Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2008

01-02-2008 | Therapy In Practice

Oesophageal Candidiasis in Elderly Patients

Risk Factors, Prevention and Management

Authors: Namal Weerasuriya, Dr Jeremy Snape

Published in: Drugs & Aging | Issue 2/2008

Login to get access

Abstract

This article reviews risk factors, prevention and management of oesophageal candidiasis (OC) in the elderly. Putative risk factors for OC in the elderly include old age itself, malignant disease, antibacterial and corticosteroid use, chronic obstructive pulmonary disease, acid suppression treatment, oesophageal dysmotility and other local factors, diabetes mellitus and HIV/AIDS. We have found evidence for a risk association between OC in the elderly and malignant disease (both haematological and non-haematological), antibacterial therapy and corticosteroid (including inhaled corticosteroids) use. We also found evidence of an association between OC in the elderly and oesophageal dysmotility or HIV/AIDS, but little direct evidence of an association between diabetes or old age per se. The literature on OC in the elderly is not large. The published series evaluating OC in this age group are small in size, often do not contain controls and mostly contain only limited information about the age of the patients. Prevention of OC is mainly the avoidance of exposure to the risk factors wherever possible. Specific measures such as highly active antiretroviral therapy in AIDS, prophylactic fluconazole when receiving chemotherapy for malignancy, using spacing devices, mouth rinsing soon after inhalation of corticosteroids and avoiding the use of cortiocosteroids just before bedtime are useful. OC is often responsive to a 2- to 3-week course of oral fluconazole, but resistance may be encountered in AIDS or in the presence of uncorrected anatomical factors in the oesophagus. Itraconazole solution, voriconazole or caspofungin may be used in refractory cases. Use of amphotericin B is restricted because of its narrow therapeutic index.
Literature
1.
Laine L, Boncini M. Esophageal disease in human immunodeficiency virus infections. Arch Intern Med 1994; 154: 1577–82CrossRefPubMed
2.
Wilcox CM, Karowe MW. Esophageal infections: aetiology, diagnosis and management. Gastroenterology 1994; 2: 188–206
3.
Roseff SA, Sugar AM. Oral and esophageal candidiasis in candidiasis: pathogenesis, diagnosis and treatment. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press Ltd, 1993: 185–203
4.
Adams F, translator. Hippocrates C460-377BC. Epidemics, book 3. Baltimore (MD): Williams & Wilkins, 1939: 23
5.
Trousseau A. Lectures on clinical medicine. Vol. 2. Delivered at the Hotel-Dieu, Paris 1868 [translated by Cormack JR]. London: New Sydenham Society, 1869
6.
Maibach HI, Kligman AM. The biology of experimental human cutaneous moniliasis. Arch Dermatol 1962; 85: 233–55CrossRefPubMed
7.
Phaosawasdi K, Rice P, Lee B, et al. Primary and secondary Candida esophagitis. Illinois Med J 1986; 169: 361–5
8.
Gentles JC, La Touche CJ. Yeasts as human and animal pathogens. In: Rose AH, Harrison JS, editors. The yeasts. Vol 1. London: Academic Press, 1969: 108–82
9.
Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 94–116
10.
Weerasuriya N, Snape J. A study of Candida oesophagitis in elderly patients attending a district general hospital in the UK. Dis Esophagus 2006; 19: 189–92CrossRefPubMed
11.
Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza A, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis 2000; 19: 96–100CrossRefPubMed
12.
Naito Y, Yoshikawa T, Oyamada H, et al. Esophageal candidiasis. Gastroenterology Jpn 1988; 23: 363–70
13.
Bhatia V, Kochlar R, Talwar P, et al. Association of Candida with cancer of the esophagus. Indian J Gastroenterol 1989; 8: 171–2PubMed
14.
Harvey CF, Mills JO, Barros AA. Oesophageal moniliasis. Br J Clin Pract 1986; 40(1): 36–40PubMed
15.
Yakoob J, Jafri W, Abid S, et al. Candidal esophagitis: risk factors in non HIV population in Pakistan. World J Gastroenterol 2003; 9: 2328–31PubMed
16.
Baskol M, Ozbakir O, Gursoy S, et al. Candida esophagitis. Turk J Gastroenterol 2001; 12: 19–22
17.
18.
Bjorn Jensen K, Stenderup A, Brown Thomsen J, et al. Oesophageal moniliasis in malignant neoplastic disease. Acta Medica Scand 1964; 175: 455–9CrossRef
19.
20.
Gundry SR, Borkon AM, McIntosh CL, et al. Candida oesophagitis following a cardiac operation and short term antibiotic prophylaxis. J Thorac Cardiovasc Surg 1980; 80: 661–8PubMed
21.
Kesten S, Hyland RH, Pruzanski WR, et al. Candida oesophagitis associated with beclomethasone dipropionate aerosol therapy. Drug Intell Clin Pharm 1988; 22: 568–9PubMed
22.
Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with fluticasone propionate. Am J Gastroenterol 2003; 98: 2146–8CrossRefPubMed
23.
Chung CH. Oesophageal candidiasis after prolonged use of inhaled corticosteroids. Hong Kong Pract 2002; 24: 248–52
24.
Simon MR, Houser WL, Smith KA, et al. Esophageal Candida as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997; 79: 333–8CrossRefPubMed
25.
26.
Mossiman F. Esophageal candidiasis, omeprazole treatment and organ transplantation. Transplantation 1993; 56: 492–3CrossRef
27.
Good A, Sharma M, Jain NP, et al. Esophageal candidiasis following omeprazole treatment: 2 cases. Indian J Gastroenterol 1995; 14: 71–2
28.
Gefter WB, Laufer I, Edell S, et al. Candidiasis in obstructed esophagus. Radiology 1981; 138: 25–8PubMed
29.
Troupin RH. Intramural diverticulosis and moniliasis. AMJ Roentgenol 1968; 104: 613–6
30.
Castillo S, Aburashed A, Kimmelman J, et al. Diffuse intra mural esophageal pseudo diverticulosis. Gastroenterol 1972; 72: 541–2
31.
deGorgolas M, Bello E, Garcia-Vazquez E, et al. In old age: AIDS review of 37 patients over 60 years old. Ann Med Intern 1999; 16: 273–6
32.
Gomez MA, Hunter R, Minino A. HIV/AIDS in a late middle aged and elderly Puerto Rican population [abstract no. 127]. Abstract search tools, National HIV Prevention Conference; 1999 Aug 29–Sep 1; Atlanta (GA)
33.
Parkman HP, Schwartz SS. Esophagitis and gastro duodenal disorders associated with diabetic gastro paresis. Arch Intern Med 1987; 147: 1477–80CrossRefPubMed
34.
Fisher BM, Lamey PJ, Samaranayake LP, et al. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. J Oral Pathol 1987; 16: 282–4CrossRefPubMed
35.
Kodsi BE, Wickremesinghe PC, Kozinn PJ, et al. Candida oesophagitis, a prospective study of 27 cases. Gastroenterol 1976; 71: 715–9
36.
Lehrer RI, Cline MJ. Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer. Cancer 1971; 27: 1211–7CrossRefPubMed
37.
38.
Walsh TH, Hamilton SR, Belitos N. Esophageal candidiasis: managing our increasingly prevalent condition. Postgrad Med 1988; 84: 193–205PubMed
39.
Silverman S, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med 1984; 39: 194–6PubMed
40.
Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 156–60
41.
Seelig MS. The role of antibiotics in the pathogenesis of Candida infection. Am J Med 1966; 40: 887–917CrossRefPubMed
42.
Gencosmanoglur R, Kurtkayer-Yapicier O, Tiftikci A, et al. Mid oesophageal ulceration and Candida associated distal oesophagitis as 2 distinct clinical patterns of tetracycline or doxycycline induced oesophageal injury. J Clin Gastroenterol 2004; 38: 484–9CrossRef
43.
Dennis H, Itkin IG. Effectiveness and complications of aerosol dexamethasone phosphate in severe asthma. J Allergy 1964; 35: 70–3CrossRefPubMed
44.
Smith MJ, Hodson ME. High dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; I: 265–9CrossRef
45.
Torak RM. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957; 22: 872–82CrossRef
46.
Tapper-Jones LM, Alfred MJ, Walker DM, et al. Candidal infections and populations of C. albicans in the mouths of diabetics. J Clin Pathol 1981; 24: 706–11CrossRef
47.
Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980; 25: 1–10CrossRefPubMed
48.
Karmeli Y, Stalnikowitz R, Eliakim R, et al. Conventional dose omeprazole alters gastric flora. Dig Dis Sci 1995; 40: 2070–3CrossRefPubMed
49.
Hendel L, Svejgaard E, Walsoe I, et al. Esophageal Candida in progressive systemic sclerosis: occurrence, significance and treatment with fluconazole. Scand J Gastroenterol 1988; 23: 1182–6CrossRefPubMed
50.
Scaringi L, Cornacchione P, Fettucciari K, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 1996; 44: 204–14CrossRefPubMed
51.
Teare JP, Spedding C, Whitehead MW, et al. Omeprazole and dry mouth. Scand J Gastroenterol 1993; 30: 216–8CrossRef
52.
Knight L, Fletcher J. Growth of C. albicans in saliva: stimulation by glucose, associated with antibiotics, corticosteroids and diabetes mellitus. J Infect Dis 1971; 123: 371–7CrossRefPubMed
53.
Odds FC, Evans EGV, Taylor MAR, et al. Prevalence of pathogenic yeasts and humoral antibodies to Candida in diabetic patients. J Clin Pathol 1987; 31: 840–4CrossRef
54.
Wilson RM, Reeves WC. Neutrophil phagocytosis and killing in insulin dependent diabetes. Clin Exp Immunol 1986; 63: 478–84PubMed
55.
Hill LVH, Tan MH, Pereira LH, et al. Association of oral candidiasis with diabetic control. J Clin Pathol 1989; 42: 502–5CrossRefPubMed
56.
57.
58.
Martinez Hernandez PL, Valencia Ortega ME, Pena Sanchez de Rivera JM, et al. HIV infection in old age: an epidemiological and clinical study in 42 patients in Madrid. Rev Clin Esp 1997; 197: 684–9PubMed
59.
Kassu A, Mekonnen A, Bekele A, et al. HIV and syphilis infection among elderly people in NW Ethiopia. Jpn J Infect Dis 2004; 57: 264–7PubMed
60.
Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients. Arch Intern Med 1991; 151: 1567–72CrossRefPubMed
61.
62.
63.
Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89CrossRefPubMed
64.
Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer and neutropenia. BMJ 1997; 314: 1238–44CrossRefPubMed
65.
Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: a prospective randomised double blind controlled study. J Infect Dis 1995; 171: 45–52CrossRef
66.
Rotstein C, Bow EJ, Laverdiere M, et al. Randomised placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: benefits based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331–40CrossRefPubMed
67.
Shuto H, Nagata M, Terashi Y, et al. Esophageal candidiasis as a complication of inhaled steroid therapy. Jpn J Allerg 2003; 52: 1053–64
68.
Kobayashi Y, Yasuba H, Kudou M, et al. Esophageal Candida as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to beclomethasone dipropionate. Int J Clin Pharm 2006; 44: 193–7
69.
Stall R, Catania JA, Pollack L. Social epidemiology of AIDS and HIV infection among older Americans. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 60–76
70.
Catania JA, Turner H, Kegeies SM, et al. HIV transmission: risk of older heterosexuals and gays. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 77–95
71.
Anderson K, Gorgone R, Marlink R, et al. Transfusion acquired HIV infection among immunocompromised persons. Ann Intern Med 1986; 105: 519–27PubMed
72.
Peterman TR, Stoneburner J, Allen H, et al. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988; 259: 55–8CrossRefPubMed
73.
Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in HIV infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–41PubMed
74.
Kaplon JE, Maur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002 Jun 14; 51(RR-8): 1–52
75.
Kaplan JE, Hansen D, Dworkin MS, et al. Epidemiology of HIV associated opportunistic infections in the US in the era of HAART. Clin Infect Dis 2000; 30: S5–14CrossRefPubMed
76.
WHO/UNAID/UNICEF. Joint news release April 2007, London
77.
Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339–46CrossRefPubMed
78.
Olmos MA, Araya V, Concetti H, et al. Oesophageal candidiasis: clinical and mycological analysis. Acta Gastroenterol Latinoam 2005; 35(4): 211–8PubMed
79.
Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662–78CrossRefPubMed
80.
Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 2003 Apr; 16(2): 241–8
81.
Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 Mar 1; 36(5): 630–7CrossRefPubMed
82.
Maschmeyer G, Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 2005; 48: 227–34CrossRefPubMed
83.
Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78(4): 161–77CrossRefPubMed
84.
Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501–17PubMed
85.
Vermes A, Guchelaar HA, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171–9CrossRefPubMed
86.
Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117: 655–60PubMed
87.
Barbaro B, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111(5): 1169–77CrossRefPubMed
88.
Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227–32CrossRefPubMed
89.
de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004 Sep 15; 39(6): 842–9CrossRefPubMed
90.
de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005 Apr 1; 21(7): 899–907CrossRefPubMed
91.
Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27: 377–83CrossRefPubMed
92.
Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients: a double-blind, multicenter placebo-controlled study: the Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996 Dec; 110(6): 1507–14CrossRefPubMed
93.
Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39(1): 1–8CrossRefPubMed
Metadata
Title
Oesophageal Candidiasis in Elderly Patients
Risk Factors, Prevention and Management
Authors
Namal Weerasuriya
Dr Jeremy Snape
Publication date
01-02-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825020-00004

Other articles of this Issue 2/2008

Drugs & Aging 2/2008 Go to the issue

Review Article

Use of β-Adrenoceptor Antagonists in Older Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Co-Morbidity

Original Research Article

Identifying Compliance Issues with Prescription Medicines among Older People

Current Opinion

Are Inhaled Systemic Therapies a Viable Option for the Treatment of the Elderly Patient?

Original Research Article

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

Therapy In Practice

Pharmacological Management of Dry Eye in the Elderly Patient

Original Research Article

Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 Years
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits